Cell surface markers for mesenchymal stem cells related to the skeletal system: A scoping review

Multipotent mesenchymal stromal cells (MSCs) have been described as bone marrow stromal cells, which can form cartilage, bone or hematopoietic supportive stroma. In 2006, the International Society for Cell Therapy (ISCT) established a set of minimal characteristics to define MSCs. According to their...

Full description

Saved in:

Bibliographic Details
Published in:	Heliyon Vol. 9; no. 2; p. e13464
Main Authors:	Fonseca, Luisa Nathalia, Bolívar-Moná, Santiago, Agudelo, Tatiana, Beltrán, Liz Daniela, Camargo, Daniel, Correa, Nestor, Del Castillo, María Alexandra, Fernández de Castro, Sebastián, Fula, Valeria, García, Gabriela, Guarnizo, Natalia, Lugo, Valentina, Martínez, Liz Mariana, Melgar, Verónica, Peña, María Clara, Pérez, Wilfran Arbey, Rodríguez, Nicolás, Pinzón, Andrés, Albarracín, Sonia Luz, Olaya, Mercedes, Gutiérrez-Gómez, María Lucía
Format:	Journal Article
Language:	English
Published:	England Elsevier Ltd 01-02-2023 Elsevier
Subjects:	Bone Bone marrow Cartilage Cell surface marker Mesenchymal stem cell (MSCs) Bone marrow Cell surface marker Cartilage Mesenchymal stem cell (MSCs) Bone
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Multipotent mesenchymal stromal cells (MSCs) have been described as bone marrow stromal cells, which can form cartilage, bone or hematopoietic supportive stroma. In 2006, the International Society for Cell Therapy (ISCT) established a set of minimal characteristics to define MSCs. According to their criteria, these cells must express CD73, CD90 and CD105 surface markers; however, it is now known they do not represent true stemness epitopes. The objective of the present work was to determine the surface markers for human MSCs associated with skeletal tissue reported in the literature (1994–2021). To this end, we performed a scoping review for hMSCs in axial and appendicular skeleton. Our findings determined the most widely used markers were CD105 (82.9%), CD90 (75.0%) and CD73 (52.0%) for studies performed in vitro as proposed by the ISCT, followed by CD44 (42.1%), CD166 (30.9%), CD29 (27.6%), STRO-1 (17.7%), CD146 (15.1%) and CD271 (7.9%) in bone marrow and cartilage. On the other hand, only 4% of the articles evaluated in situ cell surface markers. Even though most studies use the ISCT criteria, most publications in adult tissues don't evaluate the characteristics that establish a stem cell (self-renewal and differentiation), which will be necessary to distinguish between a stem cell and progenitor populations. Collectively, MSCs require further understanding of their characteristics if they are intended for clinical use.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
ISSN:	2405-8440 2405-8440
DOI:	10.1016/j.heliyon.2023.e13464